Syndax inks a $350M royalty deal; FDA pushes back decision on Organon’s eczema drug

Plus, news about Merus, Supernus and Verrica: Syndax Pharmaceuticals’ $350M deal with Royalty Pharma: The agreement is based on US sales of Niktimvo, Syndax’s graft-versus-host disease treatment. Syndax got the upfront ...